The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.M113.481473

FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (*Pcsk9*) gene expression

Rongya Tao[1], Xiwen Xiong[1], Ronald A. DePinho[2], Chu-Xia Deng[3], X. Charlie Dong[1,#]

[1]Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

[2]Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

[3]Genetics of Development and Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

Running title: Sirt6 and FoxO3 in LDL-cholesterol homeostasis

[#]Corresponding author:
Dr. X. Charlie Dong
Department of Biochemistry and Molecular Biology
Indiana University School of Medicine
635 Barnhill Drive, MS1021D
Indianapolis, IN 46202, USA
Tel: (317) 278-1097
Fax: (317) 274-4686
E-mail: xcdong@iu.edu

Key words: cholesterol, epigenetics, histone deacetylase, liver, sirtuin

This is the author's manuscript of the article published in final edited form as:
Tao, R., Xiong, X., DePinho, R. A., Deng, C. X., & Dong, X. C. (2013). FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. Journal of Biological Chemistry, jbc-M113. http://dx.doi.org/10.1074/jbc.M113.481473

Background: PCSK9 is critical for LDL-cholesterol regulation, but the epigenetic regulation of the *PCSK9* gene is not clear.

Results: FoxO3 and Sirt6 suppress the *PCSK9* gene expression and reduce LDL-cholesterol.

Conclusion: Hepatic FoxO3 and Sirt6 control LDL-cholesterol homeostasis.

Significance: FoxO3 and Sirt6 are important for cardiovascular health.

ABSTRACT

Elevated LDL-cholesterol is a risk factor for the development of cardiovascular disease. Thus, proper control of LDL-cholesterol homeostasis is critical for organismal health. Genetic analysis has identified *PCSK9* (proprotein convertase subtilisin/kexin type 9) as a crucial gene in the regulation of LDL-cholesterol via control of LDL receptor degradation. Although biochemical characteristics and clinical implications of PCSK9 have been extensively investigated, epigenetic regulation of this gene is largely unknown. In this work, we have discovered that Sirt6, an NAD^+-dependent histone deacetylase, plays a critical role in the regulation of the *Pcsk9* gene expression in mice. Hepatic Sirt6 deficiency leads to elevated *Pcsk9* gene expression and LDL-cholesterol as well. Mechanistically, we have demonstrated that Sirt6 can be recruited by forkhead transcription factor FoxO3 to the proximal promoter region of the *Pcsk9* gene and deacetylates histone H3 at lysines 9 and 56, thereby suppressing the gene expression. Also remarkably, overexpression of Sirt6 in high-fat diet fed mice lowers LDL-cholesterol. Overall, our data suggest that FoxO3 and Sirt6, two longevity genes, can reduce LDL-cholesterol levels through regulation of the *Pcsk9* gene.

Elevated LDL-cholesterol is a risk factor for cardiovascular disease (1). High LDL-cholesterol can be caused by a number of dysregulated processes, including increased cholesterol biosynthesis, increased VLDL secretion, and decreased LDL clearance (2). Genetic studies have identified mutations in at least three genes significantly contribute to autosomal dominant hypercholesterolemia (ADH), and they are LDL receptor (*LDLR*), apolipoprotein B (*APOB*), and proprotein convertase subtilisin kexin type 9 (*PCSK9*) (3). LDLR plays a major role in the LDL clearance. APOB, a protein component of

LDL, also interacts with LDLR. PCSK9 can modulate the LDL metabolism through control of the LDLR degradation in the lysosome (3).

Since the discovery of PCSK9 mutations in the ADH patients a decade ago (4), significant progress has been made in the understanding of PCSK9 biochemistry and pathophysiology (5). Now we know that PCSK9 is expressed mainly in the liver as a ~72 kDa precursor and can be auto-cleaved in the endoplasmic reticulum to a ~62 kDa mature form that is secreted to plasma. Circulating PCSK9 binds to the extracellular EGF-A domain of the LDLR and targets it for degradation in the lysosome (5). The physiological function of PCSK9 in the control of LDL-cholesterol has also been confirmed by mouse genetics. Overexpression of PCSK9 in mice leads to hypercholesterolemia and the *Pcsk*9 gene knockout in mice dramatically reduces LDL-cholesterol (6-13). Because of this biological function, PCSK9 has become a useful target for lowering LDL-cholesterol, and several clinical trials are in progress to validate the efficacy of targeting PCSK9 for cardiovascular disease (14-21).

PCSK9 gene expression can be induced by insulin and pioglitazone, and also can be suppressed by glucagon, bile acids, berberine, fibrate, and oncostatin M (22-32). PCSK9 protein levels decrease in the course of fasting and increase after feeding (22,27,29,32-34). A number of transcription factors or cofactors have been shown to regulate the PCSK9 gene expression, including sterol-response element binding proteins (SREBP-1/2), hepatocyte nuclear factor 1A (HNF1A), farnesoid X receptor, peroxisome proliferator-activated receptor gamma, liver X receptor, and histone nuclear factor P (24,28,29,33-37). However, how the *PCSK9* gene expression is controlled by epigenetic chromatin remodeling is not clear. In this work, we have identified sirtuin 6 (SIRT6) as a critical histone deacetylase for the *PCSK9* gene regulation and LDL-cholesterol homeostasis.

MATERIALS AND METHODS

Animal Studies — FoxO1 (forkhead box O1), FoxO3, FoxO1/3/4, Sirt1, and Sirt6 liver-specific knockout mice were produced by crossing floxed mice with an Albumin-Cre line from the Jackson Laboratory. Animals were maintained on the following genetic background: FoxOs floxed mice on C57BL/6J:129/Sv:FVB, Sirt1floxed mice on C57BL/6J:129/Sv, and Sirt6 floxed mice on NIH Black Swiss:129/Sv:FVB.

Genotyping was carried out as previously described (38-40). High-fat diet (60% calories from fat) was purchased from Harlan Laboratories (Madison, WI). For the VLDL secretion analysis, mice were fasted for 4 h before a dose of 500 mg/Kg body weight Triton WR1339 was injected via tail vein. Blood samples were collected and analyzed as previously described (41). All animal procedures were performed in accordance with the Guide for Care and Use of Laboratory Animals of the National Institutes of Health and were approved by the Institutional Animal Use and Care Committee of Indiana University School of Medicine.

Plasmid constructs and adenoviruses **—** For mouse *Pcsk9* gene promoter analysis, we cloned the short promoter (-128 .. +330 bp relative to the transcriptional start site) together with the 5' untranslated region (UTR) into pGL4.10 vector (Promega) using the following primers: mPcsk9-pro-Forward, 5'-GGCCCAGGAGAAGTTAGTTAATA-3', mPcsk9-pro-Reverse, 5'-ATGTCTCTGGGGAGCCAA-3'. Human FOXO3 and SIRT6 and mouse HNF1A coding sequences were cloned into pcDNA3 (Invitrogen) with FLAG or HA tag. Adenoviruses for SIRT6 and FOXO3 overexpression were generated as previously described (39,42). Mouse Pcsk9 shRNAs were designed using the BLOCK-iT RNAi Designer (Invitrogen) and DNA oligos were cloned into a pENTR/U6 vector for further adenovirus generation. The sequence of the Pcsk9 shRNA used in this work is: 5'-CAGGACGAGGATGGAGATTAT-3'. For Sirt6 gene overexpression in vivo, adenoviruses were injected into mice via tail vein at a dose of 5×10^8 pfu.

Serum and liver cholesterol analysis **—** Blood samples were collected from overnight fasted mice. Hepatic lipids were extracted as previously described (39). Total cholesterol and HDL- and LDL/VLDL-cholesterol were analyzed using assay kits from Wako Chemicals USA.

Luciferase reporter assays **—** Mouse *Pcsk9* gene promoter (also including 5' UTR) was analyzed in HEK293 cells using pGL4.10 luciferase reporter system together with an internal control Renilla luciferase reporter as previously described (39).

mRNA analysis **—** Total RNAs were isolated from cells and tissues using TRI Reagent (Sigma). Reverse transcription was performed using a cDNA synthesis kit (Applied Biosystems). Real-time PCR was performed using GoTaq qPCR Master Mix (Promega). The primers used in PCR reactions are as follows: mMttp-Forward, 5'-

ATGATCCTCTTGGCAGTGCTT -3'; mMttp-Reverse, 5'-TGAGAGGCCAGTTGTGTGAC -3'; mPcsk9-Forward, 5'-TGGAACCTGGAGCGAATTAT-3'; mPcsk9-Reverse, 5'-CACCCTGGATGCTGGTATCT-3'; mSirt6-Forward, 5'-ACGTCAGAGACACGGTTGTG-3'; mSirt6-Reverse, 5'-CCTCTACAGGCCCGAAGTC-3'. Real-time PCR data were normalized to an internal control —Ppia and relative fold changes (experimental group/control) were also calculated.

Protein analysis — Cell and tissue extract preparation, immunoprecipitation, and immunoblotting were performed as described previously (39). The following antibodies were used: anti-Actinin, anti-HA, anti-FoxO1, anti-FoxO3, anti-acetylated lysine (Cell Signaling Technology), anti-LDLR and anti-Pcsk9 (Cayman Chemical), anti-HNF1A (Santa Cruz Biotechnology), and anti-FLAG and anti-SIRT6 (Sigma).

Chromatin immunoprecipitation (ChIP) — Chromatin association analysis was performed in mouse primary hepatocytes and mouse livers, followed by chromatin preparation, immunoprecipitation with FLAG (Sigma), HA (Cell Signaling Technology), H3K9Ac, H3K56Ac and histone H3 (Millipore) antibodies and endogenous protein antibodies described above, and real-time PCR analysis, as described previously (39). ChIP DNA amount for gene promoters of interest was normalized to that of a housekeeping gene—Ppia ChIP or total histone H3 ChIP. Primers used in the ChIP PCR reactions are: mPcsk9-ChIP-Forward, 5'-CGAAACCTGATCCTTTAGTACC-3'; mPcsk9-ChIP-Reverse, 5'-ATGTCTCTGGGGAGCCAA-3'; mPpia-ChIP-Forward, 5'-CAGACCCACATTCCTGAGGT-3'; mPpia-ChIP-Reverse, 5'-AAGTCGGTGCTGTGGAAGAC-3'.

Statistical analysis — Quantitative data were presented as mean ± SEM. Significance ($p<0.05$) was assessed by two-tailed unpaired Student t-test.

RESULTS

LDL-cholesterol is elevated in hepatic Sirt6 deficient mice

Sirt6 has been previously shown to regulate hepatic triglyceride metabolism and cholesterol biosynthesis (38,43). To examine which lipoprotein-associated cholesterol might be modulated by Sirt6, we analyzed cholesterol in HDL and LDL/VLDL

fractions of sera from control floxed (LoxpT6) and Sirt6 liver-specific knockout mice (LKOT6). Whereas there was no significant difference in HDL-cholesterol, LDL/VLDL-cholesterol levels were increased 45% in the LKOT6 mice relative to the control LoxpT6 littermates (Figure 1, A and B). VLDL secretion was also increased in the LKOT6 mice compared to the control mice (Figure 1C). Microsomal triglyceride transfer protein (Mttp), an important factor for VLDL assembly and secretion, was moderately upregulated in the LKOT6 livers (Figure 1D).

Sirt6 regulates LDL-cholesterol by suppression of the *Pcsk9* gene expression

Since hepatic deficiency of Sirt6 led to elevated LDL-cholesterol but not HDL-cholesterol, we decided to further investigate the underlying mechanisms. As Pcsk9 is critically involved in LDLR turnover and LDL-cholesterol homeostasis (5), we first analyzed Pcsk9 mRNA and protein levels in control and LKOT6 livers. The results showed that Pcsk9 mRNA was increased by ~3 fold in the LKOT6 mice as compared to the control mice (Figure 2A). Consistent with an increase in Pcsk9 mRNAs, its protein level was also elevated in the LKOT6 liver (Figure 2B). Since Pcsk9 targets LDLR for degradation, we also observed a decrease in LDLR in the LKOT6 liver (Figure 2B). To verify the role of Pcsk9 in LDLR degradation, we performed Pcsk9 gene knockdown in mouse primary hepatocytes. As expected, knockdown of Pcsk9 led to a significant increase in the LDLR proteins in both wild-type and LKOT6 hepatocytes (Figure 2C).

To explore the regulatory mechanism for the *Pcsk9* gene by Sirt6, we first analyzed promoter sequences of human and mouse *Pcsk9* genes. In addition to previously identified two cis-elements—sterol response element (SRE) and HNF1A binding site, we also found a consensus binding site for FoxO transcription factors (also called insulin response element—IRE) (Figure 2D). Interestingly, the IRE is completely embedded in the HNF1A site. This raised a question whether FoxOs could affect HNF1A-activated *Pcsk9* gene expression. We performed luciferase reporter assays for the proximal promoter region of mouse *Pcsk9* gene, which also includes a part of the 5' untranslated region (UTR) containing the HNF1A binding site. To emphasize here, our nucleotide numbering (relative to the transcription start site) is different from the literature because most previous reports have numbered the *Pcsk9* promoter

constructs relative to the translation start site. The reporter assay data showed that HNF1A activated the reporter and FoxO3 suppressed the activation by HNF1A (Figure 2E). To verify that FoxO3 is associated with this region in the chromatin, we also performed chromatin immunoprecipitation (ChIP) analysis. The data revealed a strong association between the 5' UTR of the *Pcsk9* gene and FoxO3 (Figure 2F). Interestingly, while insulin reduced the association of FoxO3 to the 5' UTR of the *Pcsk9* gene, the association of HNF1A was increased (Figure 2, G and H).

To further demonstrate that FoxO3 indeed regulates the *Pcsk9* gene expression, we analyzed Pcsk9 mRNA and protein in the livers that were deficient in FoxO1, FoxO3, or FoxO1/3/4 (LKO1, LKO3, and LTKO, respectively). The data indicated that knockout of FoxO3 led to a significant increase in the *Pcsk9* gene expression in the LKO3 livers although Sirt6 mRNA levels were not significantly changed (Figure 3, A-C). As a result, hepatic LDLR protein was decreased in the liver of LKO3 mice relative to control mice (Figure 3C). To confirm the correlation between Pcsk9 and LDLR, we also performed *Pcsk9* gene knockdown in control and LKO3 mouse primary hepatocytes. As anticipated, LDLR protein levels were increased after the *Pcsk9* gene was knocked down (Figure, 3D). Similar to LKOT6 mice, LKO3 and LTKO mice also had elevated LDL-cholesterol without any significant change in HDL-cholesterol (Figure 3, E-H).

Sirt6 interacts with FoxO3 and modulates histone acetylation in the *Pcsk9* gene

Since Sirt6 is an NAD-dependent histone deacetylase (44-47), it might be recruited to the *Pcsk9* gene promoter through a transcription factor. We tested this hypothesis by performing analysis of possible protein-protein interactions between Sirt6 and HNF1A, FoxO3, or SREBP-2 by co-immunoprecipitation (co-IP). Our data showed that Sirt6 could interact with HNF1A and FoxO3 but not SREBP-2 (Figure 4, A-D and G). We also observed an interaction between FoxO3 and HNF1A in HEK293 cells and mouse primary hepatocytes (Figure 4, E and F). To examine whether Sirt6 has any effect on FoxO3 acetylation, we carried out immunoprecipitation and immunoblot analyses of FoxO3 acetylation in control and LKOT6 liver lysates. The data indicated that Sirt6 deficiency did not have any significant effect on the acetylation of FoxO3 (Figure 4H).

To assess whether Sirt6 could bring about epigenetic changes to the *Pcsk9* gene promoter, we overexpressed either GFP or Sirt6 in mouse primary hepatocytes and subsequently performed ChIP analysis of Sirt6 association and histone H3 acetylation. The results showed that Sirt6 was highly enriched at the 5' UTR of the *Pcsk9* gene and H3K9 and H3K56 acetylation levels were dramatically decreased in Sirt6 overexpressed hepatocytes (Figure 5, A and B). Conversely, those histone modifications were elevated in the liver of LKOT6 mice (Figure 5C). These data suggest that Sirt6 may be involved in these histone modifications because Sirt6 is known to deacetylate those sites (44-47). Since Sirt6 could interact with FoxO3, we also performed ChIP analysis of histone acetylation in FoxO3 overexpressed or knockout hepatocytes. Similar to Sirt6 overexpression, FoxO3 overexpression also remarkably reduced acetylation of H3K9 and H3K56 (Figure 5D). FoxO3 deficiency not only dramatically reduced association of Sirt6 with the 5' UTR of the *Pcsk9* gene but also led to an increase of acetylation of H3K9 and H3K56 when endogenous protein antibodies were used for the ChIP analyses (Figure 5, E and F).

Sirt6 overexpression lowers LDL-cholesterol in high-fat diet treated mice

To examine the potential role of Sirt6 in the protection against hypercholesterolemia, we first analyzed *Sirt6* gene expression in the liver of mice treated with a high-fat diet (HFD) for 2 months. The hepatic levels of Sirt6 mRNA and protein were decreased in the liver of HFD fed mice as compared to chow diet group (Figure 6, A and B). To test whether overexpression of Sirt6 could improve hypercholesterolemia, we injected GFP or Sirt6 expressing adenoviruses into the HFD treated mice. Two weeks later, we analyzed hepatic *Pcsk9* and LDLR gene expression and serum cholesterol. HFD induced *Pcsk9* mRNA and protein levels and Sirt6 overexpression significantly suppressed the *Pcsk9* gene expression (Figure 6, B-D). With regard to LDLR, HFD induced expression of the *Ldlr* gene, and Sirt6 overexpression further increased the LDLR protein levels (Figure 6, B-D). Whereas HDL-cholesterol levels were not changed, total and LDL-cholesterol levels were significantly decreased in the Sirt6 overexpressed mice relative to control mice on HFD (Figure 6E). These data reinforce the notion that Sirt6 plays a critical role in the LDL-cholesterol homeostasis.

DISCUSSION

In this work, we have demonstrated that hepatic Sirt6 and FoxO3 have an important role in the regulation of LDL-cholesterol homeostasis. Since Sirt6 is decreased in the livers of obese animals and humans (38,48), it implicates a potential consequence for the development of hypercholesterolemia, particularly high LDL-cholesterol. Previously, it has been reported that systemic overexpression of Sirt6 in mice can lower LDL-cholesterol under conditions of either chow or high-fat diet; however, the underlying mechanism is not clear (49). According to our data, we speculate that downregulation of the *Pcsk9* gene expression may be responsible for the low LDL-cholesterol phenotype in the *Sirt6* transgenic mice. Additionally, Sirt6 also significantly represses fatty acid and cholesterol biosynthetic genes and activates fatty acid oxidation genes (38,43). Apparently, Sirt6 has a salutary effect on lipid homeostasis.

Since Sirt6 is an NAD-dependent deacetylase and mainly targets to histone H3, it may be normally recruited by transcription factors for regulation of specific genes. With regard to the *Pcsk9* gene, SREBP-1/2 and HNF1A have been shown to play significant regulatory roles (29,31,33,34,36). Our data suggest that Sirt6 may be recruited by FoxO3 to the *Pcsk9* gene promoter in order to suppress the gene expression. FoxO transcription factors are known to have both positive and negative effects on gene regulation. The negative effects of FoxOs can be mediated by several different mechanisms, including displacement of regulatory cofactors, recruitment of co-repressor or histone deacetylase, sequestration of other transcription factors, or promotion of associated protein degradation (50). In the case of *Pcsk9* gene regulation, our data suggest that FoxO3 may suppress the HNF1A transcriptional activity on the *Pcsk9* gene promoter by displacing this transcription factor and recruiting the histone deacetylase Sirt6 as well. This regulation may occur during starvation because under that condition Sirt6 and FoxO3 are both active. As a result of the Sirt6 recruitment, deacetylation of H3K9 and H3K56 by Sirt6 creates a repressive state in the chromatin of the *Pcsk9* gene promoter to suppress the gene transcription. Additionally, reduced levels of SREBPs and HNF1A may also contribute to the downregulation of the *Pcsk9* gene during fasting (27,29,33). Upon feeding, the

activity of FoxO3 and Sirt6 is decreased and the levels of nuclear SREBPs are increased, the *Pcsk9* gene transcription is thus activated. With regard to the involvement of FoxOs in the regulation of the *Pcsk9* gene, some questions remain to be addressed in the future. First, why does FoxO3 play a major role rather than FoxO1 since FoxO1 is also highly abundant in the liver as well? In consistence with our data, previous reports have also shown that FoxO1 does not play a significant role in LDL-cholesterol regulation (36,51,52). Second, what is the role of FoxO3 in the regulation of the *Pcsk9* gene in obese and diabetic conditions? Whereas several reports have shown that feeding or insulin can induce the *Pcsk9* gene expression (23,29,53), another one has documented an increase in the *Pcsk9* expression in the liver of insulin receptor knockdown mice (36). In insulin-deficient type I diabetic rats, hepatic Pcsk9 mRNAs are dramatically decreased (53); however, in ob/ob obese mice, hepatic Pcsk9 mRNAs are also decreased by 2 fold (36). Further investigation is needed to clarify what causes differential regulation of the *Pcsk9* gene expression under those conditions.

Recently, we have reported that FoxO3 and Sirt6 also suppress the *Srebp2* gene expression in the liver (43). This suggests that both factors may have a coordinated role in cholesterol homeostasis. By regulating the *Srebp2* gene — the master regulator of cholesterol biosynthesis, FoxO3 and Sirt6 have an impact on total cholesterol levels in the circulation. With fine-tuning on the *Pcsk9* gene expression, Sirt6 and FoxO3 enhance the salutary effects by lowering LDL-cholesterol levels.

As Pcsk9 plays an important role in LDL-cholesterol homeostasis, proper regulation of the *Pcsk9* gene expression by Sirt6 and FoxO3 may contribute to cardiovascular health of organisms. It is known that both Sirt6 and FoxO3 are associated with longevity in mammals (47,54-59). Thus, it should be interesting to look into how Sirt6 and FoxO3 may influence longevity through regulation of LDL-cholesterol.

REFERENCES

1. Bulbulia, R., and Armitage, J. (2012) *Curr Opin Lipidol* **23**, 265-270
2. van der Wulp, M. Y., Verkade, H. J., and Groen, A. K. (2012) *Mol Cell Endocrinol*

3. Marais, D. A., Blom, D. J., Petrides, F., Goueffic, Y., and Lambert, G. (2012) *Curr Opin Lipidol* **23**, 511-517
4. Abifadel, M., Varret, M., Rabes, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derre, A., Villeger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) *Nat Genet* **34**, 154-156
5. Lambert, G., Sjouke, B., Choque, B., Kastelein, J. J., and Hovingh, G. K. (2012) *J Lipid Res* **53**, 2515-2524
6. Denis, M., Marcinkiewicz, J., Zaid, A., Gauthier, D., Poirier, S., Lazure, C., Seidah, N. G., and Prat, A. (2012) *Circulation* **125**, 894-901
7. Maxwell, K. N., and Breslow, J. L. (2004) *Proc Natl Acad Sci U S A* **101**, 7100-7105
8. Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y. A., and Horton, J. D. (2005) *Proc Natl Acad Sci U S A* **102**, 5374-5379
9. Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., and Horton, J. D. (2006) *J Clin Invest* **116**, 2995-3005
10. Park, S. W., Moon, Y. A., and Horton, J. D. (2004) *J Biol Chem* **279**, 50630-50638
11. Lalanne, F., Lambert, G., Amar, M. J., Chetiveaux, M., Zair, Y., Jarnoux, A. L., Ouguerram, K., Friburg, J., Seidah, N. G., Brewer, H. B., Jr., Krempf, M., and Costet, P. (2005) *J Lipid Res* **46**, 1312-1319
12. Schmidt, R. J., Beyer, T. P., Bensch, W. R., Qian, Y. W., Lin, A., Kowala, M., Alborn, W. E., Konrad, R. J., and Cao, G. (2008) *Biochem Biophys Res Commun* **370**, 634-640
13. Luo, Y., Warren, L., Xia, D., Jensen, H., Sand, T., Petras, S., Qin, W., Miller, K. S., and Hawkins, J. (2009) *J Lipid Res* **50**, 1581-1588
14. Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., and Stein, E. A. (2012) *JAMA* **308**, 2497-2506
15. Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., and Swergold, G. D. (2012) *N Engl J Med* **366**, 1108-1118
16. Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., and Pordy, R. (2012) *Lancet* **380**, 29-36
17. Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., and Stein, E. A. (2012) *N Engl J Med* **367**, 1891-1900
18. Raal, F., Scott, R., Somaratne, R., Bridges, I., Li, G., Wasserman, S. M., and Stein, E. A. (2012) *Circulation* **126**, 2408-2417
19. Koren, M. J., Scott, R., Kim, J. B., Knusel, B., Liu, T., Lei, L., Bolognese, M., and Wasserman, S. M. (2012) *Lancet* **380**, 1995-2006
20. Giugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., Abrahamsen, T. E., Wasserman, S. M., Scott, R., Sabatine, M. S., and Investigators, L.-T. (2012) *Lancet* **380**, 2007-2017
21. Dias, C. S., Shaywitz, A. J., Wasserman, S. M., Smith, B. P., Gao, B., Stolman, D. S., Crispino, C. P., Smirnakis, K. V., Emery, M. G., Colbert, A., Gibbs, J. P., Retter, M. W., Cooke, B. P., Uy, S. T., Matson, M., and Stein, E. A. (2012) *J Am Coll Cardiol* **60**, 1888-1898

22. Persson, L., Cao, G., Stahle, L., Sjoberg, B. G., Troutt, J. S., Konrad, R. J., Galman, C., Wallen, H., Eriksson, M., Hafstrom, I., Lind, S., Dahlin, M., Amark, P., Angelin, B., and Rudling, M. (2010) *Arterioscler Thromb Vasc Biol* **30**, 2666-2672
23. Persson, L., Galman, C., Angelin, B., and Rudling, M. (2009) *Endocrinology* **150**, 1140-1146
24. Langhi, C., Le May, C., Kourimate, S., Caron, S., Staels, B., Krempf, M., Costet, P., and Cariou, B. (2008) *FEBS Lett* **582**, 949-955
25. Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., and Berge, K. E. (2008) *Atherosclerosis* **201**, 266-273
26. Cao, A., Wu, M., Li, H., and Liu, J. (2011) *J Lipid Res* **52**, 518-530
27. Wu, M., Dong, B., Cao, A., Li, H., and Liu, J. (2012) *Atherosclerosis* **224**, 401-410
28. Duan, Y., Chen, Y., Hu, W., Li, X., Yang, X., Zhou, X., Yin, Z., Kong, D., Yao, Z., Hajjar, D. P., Liu, L., Liu, Q., and Han, J. (2012) *J Biol Chem* **287**, 23667-23677
29. Costet, P., Cariou, B., Lambert, G., Lalanne, F., Lardeux, B., Jarnoux, A. L., Grefhorst, A., Staels, B., and Krempf, M. (2006) *J Biol Chem* **281**, 6211-6218
30. Kourimate, S., Le May, C., Langhi, C., Jarnoux, A. L., Ouguerram, K., Zair, Y., Nguyen, P., Krempf, M., Cariou, B., and Costet, P. (2008) *J Biol Chem* **283**, 9666-9673
31. Li, H., Dong, B., Park, S. W., Lee, H. S., Chen, W., and Liu, J. (2009) *J Biol Chem* **284**, 28885-28895
32. Browning, J. D., and Horton, J. D. (2010) *J Lipid Res* **51**, 3359-3363
33. Jeong, H. J., Lee, H. S., Kim, K. S., Kim, Y. K., Yoon, D., and Park, S. W. (2008) *J Lipid Res* **49**, 399-409
34. Dong, B., Wu, M., Li, H., Kraemer, F. B., Adeli, K., Seidah, N. G., Park, S. W., and Liu, J. (2010) *J Lipid Res* **51**, 1486-1495
35. Li, H., and Liu, J. (2012) *Biochem J* **443**, 757-768
36. Ai, D., Chen, C., Han, S., Ganda, A., Murphy, A. J., Haeusler, R., Thorp, E., Accili, D., Horton, J. D., and Tall, A. R. (2012) *J Clin Invest* **122**, 1262-1270
37. Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E., and Breslow, J. L. (2003) *J Lipid Res* **44**, 2109-2119
38. Kim, H. S., Xiao, C., Wang, R. H., Lahusen, T., Xu, X., Vassilopoulos, A., Vazquez-Ortiz, G., Jeong, W. I., Park, O., Ki, S. H., Gao, B., and Deng, C. X. (2010) *Cell Metab* **12**, 224-236
39. Tao, R., Wei, D., Gao, H., Liu, Y., DePinho, R. A., and Dong, X. C. (2011) *J Biol Chem* **286**, 14681-14690
40. Paik, J. H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., Ding, Z., Miao, L., Tothova, Z., Horner, J. W., Carrasco, D. R., Jiang, S., Gilliland, D. G., Chin, L., Wong, W. H., Castrillon, D. H., and DePinho, R. A. (2007) *Cell* **128**, 309-323
41. Dong, X. C., Copps, K. D., Guo, S., Li, Y., Kollipara, R., DePinho, R. A., and White, M. F. (2008) *Cell Metab* **8**, 65-76
42. Zhao, J., Brault, J. J., Schild, A., Cao, P., Sandri, M., Schiaffino, S., Lecker, S. H., and Goldberg, A. L. (2007) *Cell Metab* **6**, 472-483
43. Tao, R., Xiong, X., Depinho, R. A., Deng, C. X., and Dong, X. C. (2013) *J Lipid Res*
44. Yang, B., Zwaans, B. M., Eckersdorff, M., and Lombard, D. B. (2009) *Cell Cycle* **8**, 2662-2663
45. Michishita, E., McCord, R. A., Boxer, L. D., Barber, M. F., Hong, T., Gozani, O., and Chua, K. F. (2009) *Cell Cycle* **8**, 2664-2666

46. Michishita, E., McCord, R. A., Berber, E., Kioi, M., Padilla-Nash, H., Damian, M., Cheung, P., Kusumoto, R., Kawahara, T. L., Barrett, J. C., Chang, H. Y., Bohr, V. A., Ried, T., Gozani, O., and Chua, K. F. (2008) *Nature* **452**, 492-496
47. Kawahara, T. L., Michishita, E., Adler, A. S., Damian, M., Berber, E., Lin, M., McCord, R. A., Ongaigui, K. C., Boxer, L. D., Chang, H. Y., and Chua, K. F. (2009) *Cell* **136**, 62-74
48. Dominy, J. E., Jr., Lee, Y., Jedrychowski, M. P., Chim, H., Jurczak, M. J., Camporez, J. P., Ruan, H. B., Feldman, J., Pierce, K., Mostoslavsky, R., Denu, J. M., Clish, C. B., Yang, X., Shulman, G. I., Gygi, S. P., and Puigserver, P. (2012) *Mol Cell* **48**, 900-913
49. Kanfi, Y., Peshti, V., Gil, R., Naiman, S., Nahum, L., Levin, E., Kronfeld-Schor, N., and Cohen, H. Y. (2010) *Aging Cell* **9**, 162-173
50. van der Vos, K. E., and Coffer, P. J. (2008) *Oncogene* **27**, 2289-2299
51. Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D. R., Le, J., Klotsas, A., Matika, R., Xiao, X., Franks, R., Heidenreich, K. A., Sajan, M. P., Farese, R. V., Stolz, D. B., Tso, P., Koo, S. H., Montminy, M., and Unterman, T. G. (2006) *J Biol Chem* **281**, 10105-10117
52. Zhang, K., Li, L., Qi, Y., Zhu, X., Gan, B., DePinho, R. A., Averitt, T., and Guo, S. (2012) *Endocrinology* **153**, 631-646
53. Niesen, M., Bedi, M., and Lopez, D. (2008) *Arch Biochem Biophys* **470**, 111-115
54. Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., Bar-Joseph, Z., and Cohen, H. Y. (2012) *Nature* **483**, 218-221
55. Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., Gellon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M. M., Mills, K. D., Patel, P., Hsu, J. T., Hong, A. L., Ford, E., Cheng, H. L., Kennedy, C., Nunez, N., Bronson, R., Frendewey, D., Auerbach, W., Valenzuela, D., Karow, M., Hottiger, M. O., Hursting, S., Barrett, J. C., Guarente, L., Mulligan, R., Demple, B., Yancopoulos, G. D., and Alt, F. W. (2006) *Cell* **124**, 315-329
56. Anselmi, C. V., Malovini, A., Roncarati, R., Novelli, V., Villa, F., Condorelli, G., Bellazzi, R., and Puca, A. A. (2009) *Rejuvenation Res* **12**, 95-104
57. Flachsbart, F., Caliebe, A., Kleindorp, R., Blanche, H., von Eller-Eberstein, H., Nikolaus, S., Schreiber, S., and Nebel, A. (2009) *Proc Natl Acad Sci U S A* **106**, 2700-2705
58. Soerensen, M., Dato, S., Christensen, K., McGue, M., Stevnsner, T., Bohr, V. A., and Christiansen, L. (2010) *Aging Cell* **9**, 1010-1017
59. Willcox, B. J., Donlon, T. A., He, Q., Chen, R., Grove, J. S., Yano, K., Masaki, K. H., Willcox, D. C., Rodriguez, B., and Curb, J. D. (2008) *Proc Natl Acad Sci U S A* **105**, 13987-13992

ACKNOWLEDGEMENTS

We thank Dr. Alfred Goldberg for kindly providing FoxO3 adenovirus. This work was supported by the grants R00DK077505 and R01DK091592 (to X. C. Dong) from the National Institute of Diabetes And Digestive And Kidney Diseases.

The abbreviations used are: ADH, autosomal dominant hypercholesterolemia; APOB, apolipoprotein B; HFD, high-fat diet; HNF1A, hepatocyte nuclear factor 1A; IRE, insulin response element; LDLR, LDL receptor; MTTP, microsomal triglyceride transfer protein; PCSK9, proprotein convertase subtilisin kexin type 9; SIRT6, sirtuin 6; SREBP, sterol-response element binding protein; UTR, untranslated region.

FIGURE LEGENDS

Figure 1. Hepatic Sirt6 knockout leads to elevated LDL-cholesterol levels. (A, B) Serum HDL- and LDL-cholesterol (HDL-C and LDL-C, respectively) measurements in 2-3 months control floxed (loxpT6) and *Sirt6* liver-specific knockout mice (LKOT6, n=10-12). (C) VLDL-cholesterol (VLDL-C) secretion analysis in control and LKOT6 mice (n=3-4). (D) Real-time PCR analysis of Mttp mRNA in the liver of control and LKOT6 mice (n=6-10). Data are mean ± SEM; *$P \leq 0.05$ by t-test.

Figure 2. Regulation of the *Pcsk9* gene by FoxO3 and Sirt6. (A) Real-time PCR analysis of Pcsk9 mRNA in the control and LKOT6 livers (n=3-5). (B) Immunoblot analysis of Pcsk9 and LDLR proteins in the control and LKOT6 livers. (C) Immunoblot analysis of Pcsk9 and LDLR proteins in mouse primary hepatocytes infected with control *GFP* (shGFP) and *Pcsk9* (shPcsk9) shRNA adenoviruses, respectively. (D) *Pcsk9* gene promoter analysis. A potential FoxO-binding element also called insulin response element (IRE, inside the box) was identified in the 5' untranslated region (UTR) of mouse *Pcsk9* gene and human *PCSK9* proximal gene promoter. Sequence numberings refer to the transcriptional start site. The previously characterized HNF1A and SREBP2 binding elements were underlined, respectively. (E) Luciferase reporter analysis of the proximal promoter (including part of the 5' UTR) of the mouse *Pcsk9* gene was performed in HEK293 cells that were transfected with respective promoter constructs with GFP, HNF1A, and FoxO3. (F) Analysis of FoxO3 association with the 5′ UTR of the *Pcsk9* gene was performed using ChIP in mouse primary hepatocytes transduced with GFP or FoxO3 expressing adenoviruses. Data are shown as fold enrichment relative to GFP. (G, H) ChIP analysis of association of FoxO3 and HNF1A with the 5' UTR of the *Pcsk9* gene in mouse primary

hepatocytes in the absence or presence of 2 nM insulin using control IgG or corresponding protein antibodies. Data are presented as fold enrichment relative to the IgG control. Data are mean ± SEM; *$P \leq 0.05$ by t-test.

Figure 3. *Pcsk9* gene expression and LDL-cholesterol were elevated in FoxO3 liver-specific knockout mice. (A) Real-time PCR analysis of Pcsk9 mRNAs in the livers of control, LKO1 (FoxO1 liver-specific knockout), LKO3 (FoxO3 liver-specific knockout), and LTKO (FoxO1/3/4 liver-specific knockout) mice (n=4-8). Control values were normalized to 1. (B) Sirt6 mRNAs were analyzed by real-time PCR in the livers of control and LKO3 mice (n=4). (C) Western blot analysis of Pcsk9 and LDLR proteins in control and LKO3 mouse livers. (D) Immunoblot analysis of Pcsk9 and LDLR in mouse primary hepatocytes transduced with shGFP or shPcsk9 adenoviruses. (E-H) Serum HDL-C and LDL-C were measured in control floxed, LKO3, and LTKO mice (n=6-8). Data are mean ± SEM; *$P \leq 0.05$ by t-test.

Figure 4. Sirt6 interacts with HNF1A and FoxO3. (A) Co-IP analysis of a potential interaction between Sirt6 and HNF1A by transfection of corresponding DNA plasmids into HEK293 cells. (B) The Sirt6-HNF1A interaction was verified in mouse primary hepatocytes by immunoprecipitation using Sirt6 antibodies. A positive control histone H3 was also included. (C) Co-IP analysis of a possible interaction between Sirt6 and FoxO3 in HEK293 cells. (D) The Sirt6-FoxO3 interaction was validated in mouse primary hepatocytes by immunoprecipitation with Sirt6 antibodies. Histone H3 was also analyzed in the IP. (E) Co-IP analysis of a potential interaction between FoxO3 and HNF1A in HEK293 cells. (F) Immunoprecipitation analysis of the FoxO3-HNF1A interaction in mouse primary hepatocytes using FoxO3 antibodies. (G) Co-IP analysis indicates no interaction between Sirt6 and SREBP-2 in HEK293 cells. (H) FoxO3 acetylation analysis of control and LKOT6 liver lysates by immunoprecipitation using FoxO3 antibodies and immunoblotting with anti-acetyl lysine antibodies.

Figure 5. FoxO3 and Sirt6 modulate histone acetylation in the chromatin of the *Pcsk9* gene. (A, B) Association of Sirt6 with the 5′ UTR chromatin of the *Pcsk9* gene and histone H3 acetylation in the same region were analyzed by ChIP in mouse primary hepatocytes transduced with GFP and Sirt6 adenoviruses. Data are shown as fold enrichment relative to the GFP control.

(C) The acetylation levels of H3K9 and H3K56 were analyzed by ChIP in the 5′ UTR of the *Pcsk9* gene in control and LKOT6 livers. Data are presented as fold enrichment relative to the LoxpT6 control. (D) The effect of FoxO3 overexpression on histone acetylation in the 5' UTR chromatin was analyzed using ChIP in mouse primary hepatocytes transduced with GFP or FoxO3 expressing adenoviruses. Data are expressed as fold enrichment relative to the GFP control. (E, F) ChIP analysis of Sirt6 association with the 5' UTR of the *Pcsk9* gene and histone H3 acetylation in control and LKO3 mouse primary hepatocytes using corresponding specific antibodies. Data in panel E are presented as fold enrichment relative to the IgG control in the Loxp3 group and data in panel F are shown as fold enrichment relative to the Loxp3 control. Data are mean ± SEM; $*P \leq 0.05$ by t-test.

Figure 6. Sirt6 overexpression reduces *Pcsk9* gene expression and serum LDL-cholesterol. (A) Sirt6 mRNA levels in in the liver of wild-type (WT) mice (n=5-8) fed chow or 2-month high-fat diet (HFD) were analyzed by real-time PCR. (B) Western blot analysis of liver proteins from chow or HFD treated WT mice infected with GFP or Sirt6 adenoviruses. (C) Quantitative analysis of Pcsk9 and LDLR proteins in Panel B. The immunoblot data were quantified by the Quantity One software (Bio-Rad) and normalized to the loading control actinin. (D) Pcsk9 and Ldlr mRNAs in the liver of chow or HFD fed mice (n=5-8) that were infected with GFP or Sirt6 adenoviruses were analyzed by real-time PCR. (E) Cholesterol measurements in the chow and HFD fed mice overexpressed GFP or Sirt6 (n=5-8). Data are mean ± SEM; $*P \leq 0.05$ by t-test.

Figure 1


A
HDL-C
HDL-C (mg/dl)
100
50
0
LoxpT6
LKOT6
B
LDL-C
LDL-C (mg/dl)
50
25
0
*
LoxpT6
LKOT6
C
VLDL-C (mg/dl)
200
150
100
50
0
*
*
*
loxpT6
LKOT6
0
30
60
90
120
Time (min)
D
Mttp mRNA
Relative values
1.5
1.0
0.5
0.0
*
loxpT6
LKOT6


A
Pcsk9 mRNA
Relative values
4
3
2
1
0
*
LoxpT6
LKOT6
B
LoxpT6
LKOT6
Pcsk9
LDLR
Actinin
C
shGFP
shPcsk9
shGFP
shPcsk9
Pcsk9
LDLR
Actinin
LoxpT6
LKOT6
D
IRE
Mouse +130 CCGGGG----CCCGTTAATGTTTAATCAGAGAGGATCTTCCGATGGGGCTCGGGGTGGCGTGATCTCCCG +195
Human -35 CCGGGGGTTCCGTTAATGTTTAATCAGATAGGATCGTCCGATGGGGCTCT---GGTGGCGTGATCTGCGC +32
HNF1A
SRE
E
Pcsk9 reporter
Normalized values
12
8
4
0
*
*
GFP
FoxO3
HNF1A
HNF1A+FoxO3
F
Pcsk9_ChIP
Fold enrichment
30
20
10
0
*
AdGFP
AdFoxo3
G
Pcsk9_ChIP
Fold enrichment
15
10
5
0
*
IgG
αFoxO3
αFoxO3
Insulin
-
-
+
H
Pcsk9_ChIP
Fold enrichment
4
3
2
1
0
*
IgG
αHNF1A
αHNF1A
Insulin
-
-
+


A
Pcsk9 mRNA
Relative values
3
2
1
0
*
*
Loxp1
LKO1
Loxp3
LKO3
Loxp
LTKO
B
Sirt6 mRNA
Relative values
2
1
0
Loxp3
LKO3
C
Pcsk9
LDLR
Actinin
Loxp3
LKO3
D
shGFP
shPcsk9
shGFP
shPcsk9
Pcsk9
LDLR
Actinin
Loxp3
LKO3
E
Serum HDL-C
HDL-C (mg/dl)
100
50
0
Loxp3
LKO3
F
Serum LDL-C
LDL-C (mg/dl)
100
50
0
*
Loxp3
LKO3
G
Serum HDL-C
HDL-C (mg/dl)
100
50
0
Loxp
LTKO
H
Serum LDL-C
LDL-C (mg/dl)
100
50
0
*
Loxp
LTKO


A
FLAG-GFP + -
FLAG-HNF1A - +
HA-Sirt6 + +
IP: FLAG
IB: HA
INPUT
Sirt6
HNF1A
GFP
B
IP: IgG αSirt6
HNF1A
Sirt6
H3
INPUT
HNF1A
Sirt6
C
FLAG-GFP + -
FLAG-FoxO3 - +
HA-Sirt6 + +
IP: FLAG
IB: HA
INPUT
SIRT6
FoxO3
GFP
D
IP: IgG αSirt6
FoxO3
Sirt6
H3
INPUT
FoxO3
Sirt6
E
FLAG-GFP + -
FLAG-HNF1A - +
HA-FoxO3 + +
IP: FLAG
IB: HA
INPUT
FoxO3
HNF1A
GFP
F
IP: IgG αFoxO3
HNF1A
INPUT
HNF1A
FoxO3
G
FLAG-GFP + -
FLAG-SREBP2 - +
HA-Sirt6 + +
IP: FLAG
IB: HA
INPUT
Sirt6
SREBP2
GFP
H
LoxpT6 LKOT6
FoxO3(Ac)
FoxO3


A
Pcsk9_ChIP
Fold enrichment
25
20
15
10
5
0
*
AdGFP
AdSirt6
B
Pcsk9_ChIP
Fold enrichment
1.6
1.2
0.8
0.4
0
AdGFP
AdSirt6
*
*
H3K9Ac
H3K56Ac
C
Pcsk9_ChIP
Fold enrichment
6
4
2
0
*
LoxpT6
LKOT6
H3K9Ac
H3K56Ac
D
Pcsk9_ChIP
Fold enrichment
1.6
1.2
0.8
0.4
0
AdGFP
AdFoxo3
*
*
H3K9Ac
H3K56Ac
E
Pcsk9_ChIP
Fold enrichment
10
5
0
*
IgG
αSirt6
IgG
αSirt6
Loxp3
LKO3
F
Pcsk9_ChIP
Fold enrichment
4.0
3.0
2.0
1.0
0.0
Loxp3
LKO3
*
*
H3K9Ac
H3K56Ac

Figure 6


A
Sirt6 mRNA
Relative levels
1.2
0.8
0.4
0.0
Chow
HFD
B
Chow+GFP
HFD+GFP
HFD+SIRT6
HA
Sirt6
Pcsk9
LDLR
Actinin
C
Normalized values
3
2
1
0
Chow+GFP
HFD+GFP
HFD+Sirt6
Pcsk9
LDLR
D
Relative levels
3
2
1
0
Chow+GFP
HFD+GFP
HFD+Sirt6
Pcsk9
Ldlr
E
Cholesterol (mg/dl)
200
150
100
50
0
Chow+GFP
HFD+GFP
HFD+SIRT6
TC
HDL
LDL

Gene Regulation:

FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression

Rongya Tao, Xiwen Xiong, Ronald A. DePinho, Chu-Xia Deng and X. Charlie Dong

J. Biol. Chem. published online August 23, 2013
